Bli medlem
Bli medlem

Du är här


Swedish Orphan Biovitrum AB (publ): Statement regarding recent speculation

The Board of Swedish Orphan Biovitrum AB (publ) notes the recent speculation
in the press and elsewhere regarding a potential acquisition of the company.

The Board confirms that it has received a preliminary and conditional
non-binding proposal in relation to a possible offer for all shares issued by
the company.

There can be no certainty that an offer will be made, nor as to the terms of
any such offer. A further announcement will be made when appropriate.


About Sobi

Sobi is an international specialty healthcare company dedicated to rare
diseases. Our mission is to develop and deliver innovative therapies and
services to improve the lives of patients. The product portfolio is primarily
focused on Haemophilia, Inflammation and Genetic diseases. We also market a
portfolio of specialty and rare disease products for partner companies across
Europe, the Middle East, North Africa and Russia. Sobi is a pioneer in
biotechnology with world-class capabilities in protein biochemistry and
biologics manufacturing. In 2014, Sobi had total revenues of SEK 2.6 billion
(USD 380 M) and about 600 employees. The share (STO: SOBI) is listed on
NASDAQ Stockholm. More information is available

For more information please contact

Media relations Investor relations
Oskar Bosson Jörgen Winroth
Head of Communications VP, Head of Investor Relations
T: +46 70 410 71 80 T: +1 347-224-0819, +1
+46 8 697 2135

Sobi announces the information set out in this press release pursuant to the
Swedish Securities Market Act. The information was submitted for publication
at 08:05 CET on 27 April 2015.

012e_Statement Speculation


This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Swedish Orphan Biovitrum AB (publ) via Globenewswire


Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.